299 related articles for article (PubMed ID: 8979114)
1. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
Nurden AT
Haemostasis; 1996 Oct; 26 Suppl 4():78-88. PubMed ID: 8979114
[TBL] [Abstract][Full Text] [Related]
2. [Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels].
Khaspekova SG; Ziuriaev IT; Iakushkin VV; Naĭmushin IaA; Sirotkina OV; Zaĭtseva NO; Ruda MIa; Mazurov AV
Biomed Khim; 2014; 60(1):94-108. PubMed ID: 24749250
[TBL] [Abstract][Full Text] [Related]
3. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
[TBL] [Abstract][Full Text] [Related]
4. The role of platelets in peripheral arterial disease: therapeutic implications.
Matsagas MI; Geroulakos G; Mikhailidis DP
Ann Vasc Surg; 2002 Mar; 16(2):246-58. PubMed ID: 11972262
[TBL] [Abstract][Full Text] [Related]
5. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness.
Armstrong PC; Dhanji AR; Truss NJ; Zain ZN; Tucker AT; Mitchell JA; Warner TD
Thromb Haemost; 2009 Oct; 102(4):772-8. PubMed ID: 19806265
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
[TBL] [Abstract][Full Text] [Related]
7. Novel platelet inhibitors.
Bennett JS
Annu Rev Med; 2001; 52():161-84. PubMed ID: 11160773
[TBL] [Abstract][Full Text] [Related]
8. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Gurbel PA
Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
[TBL] [Abstract][Full Text] [Related]
9. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
10. The genetics of antiplatelet drug resistance.
Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
[TBL] [Abstract][Full Text] [Related]
11. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Wilson JM; Ferguson JJ
Clin Cardiol; 1999 Nov; 22(11):687-98. PubMed ID: 10554682
[TBL] [Abstract][Full Text] [Related]
12. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Ito T; Koide T; Maruyama I
Thromb Haemost; 2013 Jan; 109(1):102-11. PubMed ID: 23179055
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
Schafer AI
Tex Heart Inst J; 1997; 24(2):90-6. PubMed ID: 9205981
[TBL] [Abstract][Full Text] [Related]
14. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Maree AO; Fitzgerald DJ
Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
[No Abstract] [Full Text] [Related]
15. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
17. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
[TBL] [Abstract][Full Text] [Related]
18. Platelet function testing and implications for clinical practice.
Collet JP; Montalescot G
J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
[TBL] [Abstract][Full Text] [Related]
19. [Variations in glycoprotein IIb-IIIa (alphaIIb/beta3-integrin) content in healthy donors. Influence on platelet aggregation activity and efficacy of aspirin action].
Khaspekova SG; Sirotkina OV; Shimanova IuV; Mazurov AV
Biomed Khim; 2008; 54(3):361-71. PubMed ID: 18712091
[TBL] [Abstract][Full Text] [Related]
20. Platelet function and pharmacologic inhibition.
Chaer RA; Graham JA; Mureebe L
Vasc Endovascular Surg; 2006; 40(4):261-7. PubMed ID: 16959718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]